<DOC>
	<DOCNO>NCT00790036</DOCNO>
	<brief_summary>Phase III study RAD001 adjuvant therapy poor risk patient Diffuse Large B-Cell Lymphoma ( DLBCL ) RAD001 versus match placebo patient achieve complete response first-line rituximab-chemotherapy</brief_summary>
	<brief_title>Phase III Study RAD001 Adjuvant Therapy Poor Risk Patients With Diffuse Large B-Cell Lymphoma ( DLBCL ) RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients previous histologically confirm Stage IIIIV ( Stage II bulky disease , define tumor mass 10 cm long diameter ) , time original diagnosis , diffuse large B cell lymphoma ( pathology report base original tumor tissue/lymph node acceptable meeting inclusion criterion , tumor tissue ( slides/block ) must available sent central pathology confirm diagnosis ) . 2 . Patients define poor risk IPI 3 , 4 , 5 time original diagnosis . 3 . Patients age ≥ 18 year old . 4 . Patients must achieve complete remission ( CR ) base revise IWRC ( Cheson et al 2007 ) follow first line Rchemotherapy treatment . Radiation therapy ( RT ) Rchemotherapy acceptable provide : 1 ) end 4 week prior start study drug , 2 ) case consolidation RT target initial bulky tumor mass , administer Rchemotherapy , patient already CR initiate RT . Complete remission Rchemotherapy must confirm clinical radiologic evaluation along bone marrow confirmation ( bone marrow involve lymphoma Rchemotherapy treatment ) . Local pathology report bone marrow biopsy acceptable . If bone marrow involve lymphoma Rchemotherapy treatment , bone marrow confirmation Rchemotherapy require . 5 . Patients receive minimum 5 cycle Rchemotherapy treatment maximum 8 cycle Rchemotherapy treatment . Any variation CHOP ( RCHOP14 , RCHOP21 ) acceptable . Liposomal doxorubicin , epirubicin , pirarubicin ( also know therarubicin ) acceptable . REPOCH acceptable . 6 . Patients ' last treatment Rchemotherapy must 6 14 week prior start study drug . 7 . Patients ECOG performance status ( PS ) 0 , 1 , 2 . 8 . Patients willing provide portion his/her tumor tissue original diagnosis lymph node confirm diagnosis . 9 . The following laboratory value obtain ≤ 21 day prior start study drug : Absolute neutrophil count ≥ 1000/mm3 ( 1.0 GI/L , SI unit ) Platelet count ≥ 100,000/mm3 ( 100 GI/L , SI unit ) Hemoglobin ≥ 9 g/dL ( achieve transfusion ) Total bilirubin ≤ 2 x ULN ( &gt; 2 x ULN direct bilirubin require ≤1.5 x ULN ) AST ≤ 3 x ULN Serum creatinine ≤ 2 x ULN 10 . Women childbearing potential must negative serum pregnancy test 14 day prior start study drug plus negative local urine pregnancy test Day 1 , Cycle 1 prior treatment must willing use adequate method contraception study 8 week study drug administration . 11 . Patients give write informed consent obtain accord local guideline . 12 . Patients capable swallow intact study medication tablet follow direction regard take study drug , daily caregiver responsible administer study drug . 1 . Patients evidence disease accord revise IWRC ( Cheson et al 2007 ) completion firstline Rchemotherapy treatment , prior study entry . 2 . Patients receive ongoing radiation therapy receive radiation therapy residual tumor mass &lt; 4 week start study drug . 3 . Patients previously receive systemic mTOR inhibitor ( sirolimus , temsirolimus , everolimus , etc ) . 4 . Patients evidence current central nervous system ( CNS ) involvement lymphoma . Patients prophylactic intrathecal chemotherapy CNS disease eligible . 5 . Patients transform follicular lymphoma . 6 . Patients receive ibritumomab tiuxetan ( Zevalin® ) , order avoid potential delay kidney toxicity . 7 . Patients myelosuppressive chemotherapy biologic therapy &lt; 3 week start study drug . 8 . Patients receive chronic systemic immunosuppressive agent . Inhaled topical steroid acceptable . Patients may receive stable ( increase within last month ) chronic dos corticosteroids maximum dose 20 mg prednisone ≤5 mg dexamethasone per day , give disorder lymphoma rheumatoid arthritis , polymyalgia rheumatica , adrenal insufficiency asthma . 9 . Patients active , bleeding diathesis . 10 . Patients known history HIV seropositivity . 11 . Patients know hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients . 12 . Patients severe and/or uncontrolled medical condition condition could affect participation study : unstable angina pectoris , symptomatic congestive heart failure ( NYHA II , III , IV ) , myocardial infarction ≤ 6 month prior first study drug , serious uncontrolled cardiac arrhythmia , cerebrovascular accident ≤ 6 month study drug start severely impaired lung function define spirometry DLCO ≤ 50 % normal predict value and/or O2 saturation 88 % less rest room air poorly control diabetes define fast serum glucose &gt; 2.0 x ULN active ( acute chronic ) uncontrolled infection/disorders impair ability evaluate patient patient complete study nonmalignant medical illness uncontrolled whose control may jeopardize study drug , severe hypertension control medical management thyroid abnormality whose thyroid function maintain normal range medication liver disease cirrhosis decompensated liver disease . 13 . Patients history another primary malignancy ≤ 3 year , exception nonmelanoma skin cancer carcinoma situ uterine cervix . 14 . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . 15 . Patients use investigational agent receive investigational drug ≤ 4 week prior study drug start . 16 . Patients unwilling unable comply protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diffuse large B cell lymphoma</keyword>
	<keyword>poor risk</keyword>
	<keyword>R-IPI 3-5</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>R-CHOP R-EPOCH</keyword>
	<keyword>R-CHOP</keyword>
</DOC>